Research and Markets: Global Schizophrenia Epidemiology and Patient Flow Analysis - 2012
Research and Markets (http://www.researchandmarkets.com/research/xzwbsc/global) has announced the addition of the "Global Schizophrenia Epidemiology and Patient Flow Analysis - 2012" report to their offering.
Fore Pharma announced the results of its Schizophrenia patient population study in a new report Global Schizophrenia Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Schizophrenia epidemiology, Schizophrenia diagnosed patients, and Schizophrenia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Schizophrenia derived from epidemiological analysis, percentage of patients diagnosed with Schizophrenia, and percentage of patients treated with Schizophrenia therapy.
The study helps executives estimate Schizophrenia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Schizophrenia prevalence, Schizophrenia diagnosis rate, and Schizophrenia treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
Key Features of the Report:
- Schizophrenia: Disease Definition
- Schizophrenia Patient Flow
- Schizophrenia Prevalence
- Schizophrenia Diagnosed Patients
- Schizophrenia Treated Patients
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/xzwbsc/global